Cue Biopharma, Inc.
T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof

Abstract:

The present disclosure provides T-cell modulatory multimeric polypeptide epitope conjugates comprising an immunomodulatory polypeptide ("MOD") that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide ("Co-MOD") and a conjugated alpha-fetoprotein (AFP) epitope presenting peptide. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in an AFP epitope selective/specific manner, and accordingly, for treating individuals, particularly those with hepatocellular carcinoma, pancreatic cancer, stomach cancer, colorectal cancer, hepatoblastoma, or an ovarian yolk sac tumor.